SCHEMBL6777545

SCHEMBL6777545

COC(=O)c1ccc(-c2ccc[nH]2)cc1C(=O)OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
NR4A2 P43354 4/20 0.43
CYP1A2 P05177 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
HSD17B10 Q99714 2/20 0.42
CNR1 P21554 1/20 0.42
ABL1 P00519 2/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
PDK2 Q15119 1/20 0.41
PDK4 Q16654 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
SLC6A4 P31645 3/20 0.41
SLC6A3 Q01959 3/20 0.41
SLC6A2 P23975 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24727645 0.88 HDAC1 (0.43) HDAC1HDAC6NR4A2CYP1A2ALDH1A1
SCHEMBL6466451 0.80 CA12 (0.53) NR4A2CYP1A2ALDH1A1HPGDHSD17B10
SCHEMBL29733451 0.80 CA12 (0.53) NR4A2CYP1A2ALDH1A1HPGDHSD17B10
SCHEMBL24727844 0.80 HDAC1 (0.63) HDAC1HDAC6ALDH1A1HPGDCA12
SCHEMBL9813479 0.79 CA12 (0.52) NR4A2CYP1A2ALDH1A1HPGDHSD17B10
Tert-Butyl Formate SCHEMBL27722538 0.79 ERN1 (0.36) HDAC1HDAC6NR4A2CYP1A2ALDH1A1
SCHEMBL9813482 0.78 NR4A2 (0.49) NR4A2CYP1A2ALDH1A1HPGDHSD17B10
SCHEMBL14252250 0.76 NR4A2 (0.59) NR4A2ALDH1A1HPGDSLC6A4SLC6A3
SCHEMBL70440 0.76 NR4A2 (0.59) NR4A2ALDH1A1HPGDSLC6A4SLC6A3
SCHEMBL6045699 0.75 SLC6A3 (0.51) NR4A2ALDH1A1HSD17B10CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6699870-B2 Phthalazine compounds and therapeutic agents for erectile dysfunction EISAI CO., LTD. (JP) 2004-03-02 US disclosed
US-20030105074-A1 Phthalazine compounds and therapeutic agents for erectile dysfunction EISAI CO., LTD. 2003-06-05 US disclosed
US-6498159-B1 SUCH AS 4-((3-CHLORO-4-METHOXYBENZYL)AMINO)-1-((4-HYDROXY-4 -HYDROXYMETHYL)PIPERIDINO)-6-PHTHALAZINE CARBONITRILE EISAI CO., LTD. (JP) 2002-12-24 US disclosed
EP-1057819-A1 PHTHALAZINE DERIVATIVES AND REMEDIES FOR ERECTILE DYSFUNCTION Eisai Co., Ltd. (JP) 2000-12-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105074-A1 Phthalazine compounds and therapeutic agents for erectile dysfunction CLIC1, CBR1, CBR3 HDAC1 14/4885HDAC6 171/4885NR4A2 392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.